Due to technical maintenance the webshop is closed until January 3, 4. We wish you a successful 2024!
LEIDEN June 2, 2023 - BIOKÉ announced it has signed a distribution agreement with Scale Biosciences (ScaleBio), a pioneer in single-cell sequencing and combinatorial indexing technologies, to distribute their technology in the Netherlands, Belgium, and Luxembourg (Benelux), effective immediately.
ScaleBio’s scRNAseq solution, built upon the company’s patented and disruptive combinatorial indexing technology, enables the indexing of up to 96 samples and hundreds of thousands of cells in a single experiment at a fraction of the cost of on-market single-cell systems. The scRNAseq solution supports the profiling of cell lines, PBMCs and nuclei (disassociated from tissue) sample types, and includes a fixation kit for the fixation, storage, and transport of samples. The scRNAseq solution is accessible and easy-to-adopt, not requiring expensive instrumentation, is scalable and robust to support larger and more complex single-cell studies and generates high-quality data for biological insights.
“We look forward to offering ScaleBio’s single-cell profiling and analysis solutions to our customers. They will benefit from a unique combination of increased throughput, multi-omics support, high data quality and lower overall prep and sequencing costs,” says Robert Hovingh, Sales Manager Europe BIOKÉ.
“By partnering with BIOKÉ, Scale Biosciences can leverage their expertise to offer customers more tailored solutions and support throughout the research process. This partnership has the potential to benefit both companies and their customers by combining expertise and resources to offer more comprehensive solutions for single cell analysis.,” says Melanie Masuda, Director of Commercial Development at Scale Biosciences.
Learn more about the technology
About Scale Bioscience
ScaleBio is a single-cell sequencing solutions company founded by a multidisciplinary team of scientists and technologists, including Garry Nolan, Jay Shendure, Cole Trapnell, and Frank Steemers, who bring combined expertise in next-generation sequencing, genomics, proteomics, and bioinformatics, and share a common mission for unlocking the potential of single-cell analysis at scale by eliminating barriers to discovery. ScaleBio is financed by leading life sciences tools investors ARCH Venture Partners, BNG and Tao Capital. For additional information, visit https://scale.bio/.
About BIOKÉ
Founded in 2004, BIOKÉ is an experienced and knowledgeable company that provides innovative products with the highest quality in the life science industry throughout Europe. BIOKÉ delivers unique and high-performance products for genomics, protein analysis and cell biology. In July 2009 Cell Signaling Technology, Inc. (CST) acquired BIOKÉ BV and BIOKÉ became a business unit of Cell Signaling Technology. BIOKÉ holds offices in Leiden, the Netherlands.